Please login to the form below

War on drugs: the use of controlled substances in medicine

Infamously coined America’s ‘public enemy number one’ by President Nixon, are controlled substances a fundamental missing part of modern medicine? By Emma Gorton, Senior Director at Hanover Communications

On 17 June 1971, President Nixon declared drug abuse as America’s ‘public enemy number one’ and launched what has since become known as the ‘war on drugs'.

Controlled substances were from thereon positioned as a common enemy to unite people, and many argue that President Nixon used the war on drugs as a political tool to criminalise certain groups who were viewed as enemies of the Nixon administration.

Nixon’s war on drugs meant that all research into controlled substances’ efficacy on health conditions was halted. These substances were deemed the enemy and that was that.

Now, fifty years later in 2020, we are seeing a rise in the number of clinical trials investigating controlled substances for the treatment of medical conditions; medical conditions such as mental disorders which are now among the leading causes of ill-health and disability worldwide.

Psilocybin (aka magic mushrooms) has shown promise in treating a variety of difficult-to-treat health conditions such as depression and cancer-related anxiety. Ketamine has shown efficacy in the treatment of mental health conditions with the FDA approving a version of it, esketamine nasal spray, in March 2019 for treatment-resistant depression. Earlier this year, the FDA granted application for an Expanded Access Program for MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder. And not forgetting cannabis, a drug which is booming and infiltrating all areas of health and wellness including skincare and beauty treatments. It has shown promise in mental health conditions, skin conditions and a cannabis-based medicine is now available on the NHS for the treatment of epilepsy.

This shouldn’t come as a surprise to us as in our earliest days as a species, we used controlled substances in a medicinal way. In shamanism, for example, psychedelics would be commonly administered for those with severe medical or psychological problems as part of healing ceremonies.

So why are we in the western world in 2020, only just kickstarting our research into these breakthrough substances now?

Nixon’s war on drugs certainly plays a role and has had a significant detrimental impact on the advancement of treatment for mental health conditions. If Nixon hadn’t launched his war on drugs back in the 70s, we would have an extra fifty years of research into controlled substances behind us and mental health conditions may  be better managed and treated. It is frightening how little we actually know about the brain and the war on drugs has contributed to this lack of progress.

Looking to the future, the rise of clinical trials in controlled substances is something to be optimistic about, however, bringing these medicines to market will have challenges. Most significantly, there are fifty years’ worth of bad reputation to contend with, so ultimately even if these substances are found to be efficacious there will be a huge need to change public perception and to ensure the correct policy is in place so patients can access the treatments. Our speciality of mix of communications, policy and market access at Hanover is designed to do just that.

15th April 2020

Share

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
70 Gray's Inn Road
London
WC1X 8BT
United Kingdom

Latest content on this profile

Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds
Timed to coincide with International Women’s Day, the Government’s Women’s Health Strategy for England landed at a moment of national contemplation about women’s place in society more generally, following the murder of Sarah Everard. In her latest blog, Hanover Health’s Jennifer Blainey breaks down the strategy and considers what needs to happen for it to succeed.
Hanover Communications
COVID-19 has changed the way we must talk about treatment for rare diseases
The turbulence of the last year has brought into sharp focus the difficult choices to be made when it comes to healthcare prioritisation. There is now more of a reluctant acceptance that there will always be someone or something that will miss out so the ‘unjust’ emotional argument won’t resonate in the same way anymore. In her latest blog, Hanover Health’s Emma Gorton considers why in the wake of Covid-19, communicators must change their narrative around the treatment of rare diseases.
Hanover Communications
What does the COVID-19 vaccine mean for the future of R&D?
Amid a pandemic, time is a luxury the world cannot afford. The last 12 months have contradicted what we once thought about the speed of progressing scientific research. Here Shannon Lacombe explores the factors that have contributed to the unprecedented speed of vaccine development from early-stage research to mass public rollout. She also looks at what precedent this has set for the future of research and development timelines and the assumptions and status quo that will now be challenged as a result.
Hanover Communications
Is the world ready for a COVID-19 vaccine?
At the beginning of November, Pfizer and BioNTech announced that their vaccine candidate was more than 90% effective at preventing COVID-19 infection. Since then, other good news has followed, with collaborations, including Moderna and AstraZeneca, publishing similarly positive results. This is a phenomenal feat that would have been unimaginable just one year ago. But a vaccine is only as effective as its deployment and uptake. There should be no doubt that as soon as the first COVID-19 vaccine was approved, a very difficult logistics game ensued. The reality is that a COVID-19 vaccine will present a whole new unfamiliar set of operational challenges. There are currently more than 170 candidate vaccines in development, each with its own benefits and each with its own challenges. Here, we explore some of those challenges and reflect on what must be considered by health systems and governments to set us on track towards pandemic recovery.
Hanover Communications
It's out - so what?
The European Commission’s Pharmaceutical Strategy has been published and the Commission has presented its priorities for the coming years. The focus is on patient access to affordable treatments; ensuring and boosting the competitiveness of the European pharmaceutical sector and making sure that the EU will have a strong voice on global health and pharmaceutical policy. Stakeholders now need to make sure that their voices are heard and included in upcoming proposals and, eventually, in legislation. By Jenni Kortelainen, Hanover EU
Hanover Communications
Let's be ambitious for patients and life sciences investment in Global Britain
“Take up of new medicines in the UK continues to be slow by international standards”. Since this Pharmaceutical Industry Competitiveness Task Force report in 2005, there have been at least five UK life science strategies plus three PPRS or VPAS deals. All have promised to accelerate access of new medicines to patients. Sadly, 12 years on, the 2017 Life Sciences Industrial Strategy could only restate the challenge: “Evidence demonstrates that access to and diffusion of products in the NHS is often slower than in some comparable countries”. Can we ever break this cycle? By Andrew Harrison, Group Managing Director of Hanover Health.
Hanover Communications